Myelofibrosis (MF) is a hematological malignancy characterized by disrupted blood cell production and bone marrow scarring. Two high-priced JAK inhibitors (Incyte’s Jakafi and BMS’s Inrebic)…
TNF-α inhibitors (e.g., Janssen's Remicade, AbbVie’s Humira) are well entrenched in the U.S. ulcerative colitis (UC) and Crohn’s disease (CD) markets. Newer therapies that offer…
TNF-α inhibitors (e.g., Janssen's Remicade, AbbVie’s Humira) are well entrenched in the U.S. ulcerative colitis (UC) and Crohn’s disease (CD) markets. Newer therapies that offer…
Clarivate Epidemiology's coverage of Autism Spectrum Disorder (ASD) comprises epidemiological estimates of key patient populations across 7 countries. We report the prevalence of ASD for each…
Treatment of small-cell lung cancer (SCLC) has long been dominated by chemo(radio)therapy, but the standard of care for first-line extensive-stage SCLC recently changed, following the FDA’s…
Systemic sclerosis (SSc) is a rare, progressive, debilitating autoimmune disorder characterized by skin fibrosis, systemic inflammation, and vasculopathy that manifests as Raynaud’s disease, skin…
Clarivate Epidemiology's coverage of VTE comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report diagnosed prevalence of obesity/overweight for…
Clarivate Epidemiology's coverage of venous thromboembolism (VTE) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the diagnosed incidence of…
Clarivate Epidemiology's coverage of venous thromboembolism (VTE) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the diagnosed incidence of…
Clarivate Epidemiology's coverage of venous thromboembolism (VTE) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the diagnosed incidence of…
Clarivate Epidemiology's coverage of venous thromboembolism (VTE) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the diagnosed incidence of…
Clarivate Epidemiology's coverage of venous thromboembolism (VTE) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the diagnosed incidence of…
Clarivate Epidemiology's coverage of venous thromboembolism (VTE) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the diagnosed incidence of…
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key venous thromboembolism patient populations covering 171 countries…
